Helomics Launches CellFx, A Key Research Component
Helomics® Launches CellFx™, A Key Research Component of their Precision Cellular Analytical Platform (PCAP™) Further Expanding their Comprehensive Tumor Profiling Offering to Patients, Physicians and Life Science Industry
The CellFx™ platform allows for a personalized full tumor biology characterization of a patient’s tumor
PITTSBURGH - February 8, 2016 - Helomics® Corporation (Helomics®), a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services announced today that it will be launching, in March 2016, CellFx™, a new research component of the company’s Precision Cellular Analytical Platform called PCAP™.
The CellFx platform combines a proprietary high resolution digital imaging process with genomic and proteomic analyses on both live and fixed tumor tissue. CellFx will be used to further enhance Helomics’ tumor biology research and clinical test development efforts with collaborators and partner-clients in academia, and in the diagnostics and pharmaceutical industries. Based on greater than 15 years of experience and proprietary know-how in the ex vivo culture of human primary tumor cells, the CellFx platform is an important tool that will lead to better informed patient treatment decisions; a deeper understanding of the molecular and biochemical basis of malignancy; and the identification and development of new anti-cancer therapies, new treatment markers, and companion diagnostics.
Neil J. Campbell, President & CEO of Helomics said, “The CellFx platform gives us a proprietary and very unique ability to study tumor biology on a truly personalized level by analyzing a patient’s own tumor cells. Using our CellFx and PCAP platforms, we can investigate changes in cell morphology, tumor biochemistry, and gene or protein expression over time or drug treatment as never before. As a key component of our proprietary PCAP platform, CellFx enables us to thoroughly study the biology of individual human tumors.”
The core of the CellFx™ platform is Helomics’ ability to grow primary human tumors in tissue culture. Physicians and researchers send tumor specimens to Helomics where proprietary methods are used to grow the patient’s tumor. This allows for the temporal analysis of gene and protein expression associated with tumor cell proliferation, tumor cell death, drug response, and/or drug toxicity. Helomics’ ability to grow primary human tumors in a multi-dimensional culture has been meticulously refined for over 15 years and is currently in its fourth generation of tumor biology elucidation.
The PCAP™ platform is the basis of Helomics’ comprehensive tumor profiling capability. The platform consists of a suite of technologies for the live and fixed cell analysis of changes in a tumor’s gene regulation, protein expression, and cellular morphology over time or with treatment.
About Helomics® Corporation, Inc.
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer. Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.
This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and other important factors could cause actual results to differ materially from those communicated in any forward-looking statements, information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.